Clinical inertia as a clinical safeguard

JAMA

Volumn 305, Issue 15, 2011, Pages 1591-1592

  Giugliano, Dario ^a   Esposito, Katherine ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANDOLAPRIL; VERAPAMIL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; ARTICLE; BLOOD; DECISION MAKING; DIABETES MELLITUS; MASS COMMUNICATION; STANDARD;

DECISION MAKING; DIABETES MELLITUS; DIFFUSION OF INNOVATION; DYSLIPIDEMIAS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PATIENT CARE; PRACTICE GUIDELINES AS TOPIC;

EID: 79955040917     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.490     Document Type: Note

References (10)

1. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001; 135(9):825-834. (Pubitemid 33051266)
2. National Center for Health Statistics. Health, United States, 2009: With Special Feature on Medical Technology. Hyattsville, MD: National Center for Health Statistics; 2010.
3. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009; 32(1):187-192.
4. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: Time for a reappraisal. Diabetologia. 2010;53(10):2079-2085.
5. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. (Pubitemid 351831356)
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-2050.
7. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61-68.
8. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-1585.
9. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: A meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
10. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy. Arch Intern Med. 2010;170(18):1648-1654.